Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumors. - Wikidata - wikimedia - TriplyDB

Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumors.

Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumors.

http://www.wikidata.org/entity/Q40356007

about

What lessons can be learned from γδ T cell-based cancer immunotherapy trials?γδ T Cell Immunotherapy-A Review γδ T cells for cancer immunotherapy: A systematic review of clinical trials Expanded Human Blood-Derived γδT Cells Display Potent Antigen-Presentation Functions.Metabolic engineering of Salmonella vaccine bacteria to boost human Vγ2Vδ2 T cell immunity.Clinical applications of gamma delta T cells with multivalent immunity.A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.Potential of human γδ T cells for immunotherapy of osteosarcoma.Quantitative peripheral blood perturbations of γδ T cells in human disease and their clinical implications.γδ T cells as a potential tool in colon cancer immunotherapy.γδ T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy.Cancer Immunotherapy Using γδT Cells: Dealing with Diversity.γδ T cell therapy for the treatment of non-small cell lung cancer.Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer.Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity.Current Advances in γδ T Cell-Based Tumor Immunotherapy.CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.Dual Face of Vγ9Vδ2-T Cells in Tumor Immunology: Anti- versus Pro-Tumoral Activities.Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias.Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells.

P2860

Q26849323-6B1EFEAA-93E1-4903-B249-A0ACB5105AD4 Q26995102-A2E0B563-5AA3-4D1D-8B5C-43A0850FE766 Q27021705-77DCB442-3419-4FA3-BF6E-F8BBE347505D Q33938500-67828720-BABA-4278-B182-7E09A96EAA09 Q34560345-8668D58E-17FF-4513-AFF9-C4CF38A70206 Q34677859-65F573C0-480E-4B1A-8270-4286F4CCE150 Q34743969-E50F2C06-4F5F-4C2D-9406-D6E4809F37E9 Q35226178-534E7D12-7934-43E4-9168-9429461C5DB4 Q37729133-FC7ED1FA-4858-48BF-B783-5133E8025E1A Q38052064-9BF5E875-DE08-45AC-86F4-7886F9780A32 Q38152686-5AE9B94A-98CE-45C2-82FB-D80D2ED5E36B Q38262257-79071387-E854-49B6-AE97-7E9E9339C51D Q38271585-13CFE6AB-080F-469C-B02E-C77393D45593 Q38283536-55E15E28-2372-4D0B-96B0-6DC9F8A00C80 Q38390100-9434ECE8-F8EF-4FCD-9B8F-318432BA67CA Q38787725-FB4CA9CE-FD1D-46AB-B670-38339EB394F9 Q40252845-43CD4852-343F-4487-BB90-2269C5F5CAFA Q47100174-B44B0D30-01A4-4855-98FD-6C0B606209A4 Q48124547-AC5A3036-C250-495B-A873-2C7D26112FE4 Q50144881-B34E19B1-8CB0-4F1E-8F28-00329FC9B4E8 Q54940475-A11BBFD4-7B59-4A65-8ED1-863FB75E2B73 Q55311835-D75F2F0E-1AF8-4EBA-955E-F52F8A512E0C Q55339238-871537BE-A63A-4C4D-9AB5-93A4CBB51B20

P2860

Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumors.

http://www.wikidata.org/entity/Q40356007

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Phase I study of bromohydrin p ...... in patients with solid tumors.

@en

type

label

Phase I study of bromohydrin p ...... in patients with solid tumors.

@en

prefLabel

Phase I study of bromohydrin p ...... in patients with solid tumors.

@en

P1433

Q40356007-C10A8709-3BA6-4A4F-8154-00E5D0DA9B47

P1476

Q40356007-C3457F73-9C11-4EA6-9BEA-6C7E21767BAA

P2093

Q40356007-09E2640F-5993-4545-A72D-7699744571F9

Q40356007-1C312AA5-BB09-44FB-8306-C1BDE1BE2756

Q40356007-324CCBD0-8E15-41F0-9D06-932D05478988

Q40356007-744AB463-D2BA-499C-B8B1-A392BA42747B

Q40356007-7F731697-6B09-4070-ADCC-44FC9D71DDE0

Q40356007-81F930E9-A7E4-4858-938A-F59F33C922BD

Q40356007-91435026-E65D-470F-ABE3-8A51C0FF5B2B

Q40356007-97C60E35-2EC4-442E-94F3-6A12474620FC

Q40356007-A4C44A98-87A3-4CC2-8D3F-7924113BBEBE

Q40356007-AA2F97BC-BDE8-4E77-8517-2A5275B37944

P2860

Q40356007-4F3628BB-335D-46C4-936E-50FDD666AE07

Q40356007-74BF29D4-FBC9-4106-BA4F-A70D1922DF3C

Q40356007-BFF88403-5C48-49E1-8427-8C1B48DBFC67

Q40356007-D93F08FC-4811-48BD-B3C1-A9602E2CD9DE

Q40356007-E1EE3925-019A-4E92-9457-76E219EB4912

Q40356007-EE5D9BFA-8D69-4482-934D-A5701A89F80F

P2888

Q40356007-93F4BE36-FF31-4C88-BFDC-85E46BBB1ACA

P304

Q40356007-8FAA1C16-5F95-4F19-9847-1D76FBB2F797

P31

Q40356007-B15ADAB5-8DF6-4695-A623-C32540C95077

P356

Q40356007-CFD9DD4B-DF28-4540-AA38-D9474AADD687

P433

Q40356007-79D094B6-39A1-4D16-B8F3-CA039DA2CCEA

P478

Q40356007-F17C3BFC-AA89-45DE-907B-01DD7999B246

P577

Q40356007-986BD280-C7B8-482C-8AB6-0AE1D297F599

P6179

Q40356007-AE67CC5D-4F3E-4BD9-A05B-8E501C37F64C

P698

Q40356007-6C734C71-9CAD-4E82-9F87-4828233E9146

P356

S00262-010-0879-0

P1433

Cancer Immunology, Immunotherapy

P1476

Phase I study of bromohydrin p ...... in patients with solid tumors.

@en

P2093

Céline Galéa

http://www.w3.org/2001/XMLSchema#string

Fabien Calvo

http://www.w3.org/2001/XMLSchema#string

Frédéric Rolland

http://www.w3.org/2001/XMLSchema#string

Heriberto Bruzzoni-Giovanelli

http://www.w3.org/2001/XMLSchema#string

Hélène Senellart

http://www.w3.org/2001/XMLSchema#string

Hélène Sicard

http://www.w3.org/2001/XMLSchema#string

Jaafar Bennouna

http://www.w3.org/2001/XMLSchema#string

Jérome Tiollier

http://www.w3.org/2001/XMLSchema#string

Marie Audrain

http://www.w3.org/2001/XMLSchema#string

Marie Rimbert

http://www.w3.org/2001/XMLSchema#string

P2860

V gamma 9V delta 2 T cell response to colon carcinoma cells.

Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.

Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.

Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.

Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: the role of exogenous IL-2.

In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model.

P2888

s00262-010-0879-0

P304

1521-1530

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-010-0879-0

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1046313967

http://www.w3.org/2001/XMLSchema#string

P698

20563721

http://www.w3.org/2001/XMLSchema#string